Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Lecture one
Anticancer drug
| Term | Definition |
|---|---|
| Curative cancer by chemotherapy | choriocarcinoma (advance stage); Hodgkin's disease, carcinoma of tests; acute leukemia (some case) |
| Biologic therapy | immunotherapy (involves stimulating the host's immune system to fight the cancer) |
| Agent of Biologic therapy | cytokines (Produce by DNA tech). tumor vaccines; interferons (IFNs); interleukins (ILs); monoclonal antibodies (mAbs) |
| Adjuvant therapy | the use of systemic agents to eradicate micrometastatic disease following localized modalities such as surgery and radiation or both. |
| Palliative therapy | relieving and preventing the suffering of patients |
| Alkylating agents | Nitrogen mustards; ethylenimine & methylmelamines; alkyl sufonates; nitrosourea; triazenes and platinum complexes |
| Antimetabolites | folic acid analogs; pyrimidine analogs and purine analogs |
| Natural products | anti mitotic drugs; epipodophyllotoxins; camptothecin analogs; antibiotics |
| Hormones and antagonists | estrogens; androgens and their antagonists (tamoxifen, flutamide) |
| Miscellaneous agents | substituted urea (hydroxyurea); enzymes; tyrosine kinase inhibitors; monoclonal Abs |
| Factor affect chemotherapy | drug resistance; tumor cell heterogeneity; does intensity; patient-specific factors |
| Drug resistance | 1) decrease activation of drug; 2) decrease drug uptake or incase efflux; 3) change in target enzymes; 4) increase repair ability of cell damage; 5) increase drug inactivation |
| Drug resistance protein | MRP (ABCC); BCRP (ABCG2/MXRABCP) |
| General inhibitors of organic anion transport | Probeanecid; sulfinpyrazone; indomethacin |
| Inhibitors or P-glycoprotein and MRPs | PAK104P; Verapamil; cyclosporinA; genistein; MK571; ONO1078; TKI |
| GSH-dependent inhibitors of MRP1 | AgosteolA; LY475776; LY402913 |
| Inhibitors of ABCG2/BCRP | Fumitremorgin C(FTC); GF120918; TKIs |
| Taxanes, Paclitaxel (Taxol) | Ovarian carcinoma MOA: Promotes microtubule formation, inhibits the replication and also enhance the radiation therapy. |
| Docetaxel (Doc, Taxotere, TXT) | It is analog of Taxol. Breat, ovarian cancer; NSCLC |
| Camptothecin's analog, topotecan | Advance ovarian carcinoma, some efficacy on lung cancer. MOA: inhibits topoisomerase I |
| Irinotecan (CPT-11) | metastatic colorectal cancer. |
| Small molecule compounds (TK inhibitors) | Imatinib mesylate (Gleevec, ST1571); Gefitinib (Iressa, ZD1839); Erlotinib (Taceva); Sutent (sunitinib malate, formerly SU-11248); Trastuzumab (Herceptin); Lapatinib or lapatinib ditosylate (GW572016); Dasatinib (Sprycel); Nilotinib (Tasigna) |
| Imatinib mesylate (Gleevec, STI571) | Chronic myelogenous leukemia (CML); Gastrointestinal stromal tumor (GIST) |
| Gefitinib (Iressa, ZD1839) | NSCLS |
| Erlotinib (Tarceva) | NSCLS |
| Sunitinib malate (SU11248) suttent | MOA: TKis, also inhibiting blood vessel growth renal cel carcinoma |
| Trastuzumab (Herceptin) | breast cancer |
| apatilnib ditosylate, GW572016) | breast and lung cancer |
| Dasatinib (Sprycel) | chronic phase (CP) accelerated phase (AP) myeloid blast (MB) lymphoid blast (LB) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) |
| Nilotinib (Tasigna) | drug resistant chronic myelogenous leukemia (CML) |
| Everolimus (Afinitor) | Kidney cancer |
| Bevacizumab (Avastin) | colon cancer; NSCLC; breast cancer |
| Crizotinib (Xalkori, Pfizer) | NSCLC |
| Vemurafenib (Zelboraf) | melanoma |
| Nanoparticle albumin-bound (nab)-paclitaxel (Abraxane, Celgene) | metastatic pancreatic cancer |
| Bevacizumab (Avastin) | last stage cervical cancer |
| Nivolumab | melanoma |
| Pembrolizumab | melanoma |
| Beleodaq (belinostat) | peripheral T-cell lymphoma MOA: Histone deacetylase (HDAC) inhibitor |
| Vectibix (panitumumab) | metastatic colorectal cancer |
| Imbruvica (ibrutinib) | chronic lymphocytic leukemia |
| Zydelig (idelalisib) | chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) MOA: phosphoinositide 3-kinase (PI3K) delta inhibitor |
| Velcade (bortezomib) | multiple myeloma |
| Avastin (bevacizumab) | cervical cancer |
Created by:
wind1980
Popular Pharmacology sets